Should HIV patients be considered a high risk group for the development of prostate cancer?

Quatan, N; Nair, S; Harrowes, Fran; Hay, Phillip

doi:10.1308/003588405x60696

Cited by 18 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient survived his acute event and was started on androgen deprivation therapy. 20 Quatan et al 15 present a 58-yearold man who was hospitalized with infective myositis of the left iliacus muscle and was found to have a PSA of 5638 ng ml À1 . A bone scan confirmed metastatic disease throughout his axial skeleton.…”

Section: Symptomatic Detectionmentioning

confidence: 99%

See 1 more Smart Citation

HIV and prostate cancer: a systematic review of the literature

Silberstein

Downs

Lakin

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Malignancy occurs with increased frequency in the HIV-positive population. The true incidence of prostate cancer in this population is unknown. In the few cases that have been presented in the literature, prostate cancer in HIV-positive men appears to behave much like it does in HIV-negative men. Prostate cancer is the most common malignancy in men and the second leading cause of cancer death. Approximately 800 000 men in the United States are HIV positive, and innovative therapies have dramatically improved survival. HIV disproportionately impacts ethnic groups with increased risk of prostate cancer and has been associated with increases in the incidence of certain malignancies. Despite the high prevalence of both diseases, there is relatively little literature about prostate cancer in HIV-positive patients. There is no consensus on how to screen or treat this patient population. We review the literature with regards to incidence, screening, treatment, and outcomes of this poorly characterized population. We briefly discuss the impact of highly active antiretroviral therapy and testosterone supplementation in the development of prostate cancer. A systematic review of the literature was conducted using MEDLINE key words 'HIV,' 'prostate,' 'prostate cancer' and 'AIDS.' Manual bibliographic review of cross-referenced items was also performed. A total of 176 unique abstracts and publications were reviewed; many authors provided data on the incidence of HIV and various malignancies including prostate cancer. Twelve unique publications providing detailed information on 60 patients with HIV and prostate cancer were identified. Prostate cancer is a common malignancy in HIV-positive men. With improved therapies for HIV and increasing survival, the importance for screening and treating prostate cancer is increasing. Acute outcomes of treatment do not demonstrate increased acute morbidity; however long-term outcomes have not been reported.

show abstract

Section: Symptomatic Detectionmentioning

confidence: 99%

“…The patient had a good initial response to androgen deprivation therapy but developed androgen-insensitive PCa approximately 1 year after diagnosis. 15 …”

Section: Symptomatic Detectionmentioning

confidence: 99%

HIV and prostate cancer: a systematic review of the literature

Silberstein

Downs

Lakin

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…89 Some clinicians advocate PSA screening of HIV-positive patients in their early forties because of the potential for prostate cancer to present in a disseminated manner with nonspecific features. 87,90 HIV-positive patients who have asymptomatic prostate cancer should be offered all possible treatment options, including surgery, radiation, androgen deprivation, and observation. Some clinicians believe that laparoscopic or robot-assisted surgery should be performed when possible to minimize the risk of postsurgery complications.…”

Section: Prostate Cancermentioning

confidence: 99%

Urologic complications of HIV and AIDS

2009

View full text Add to dashboard Cite

“…Although the impact of CD4 lymphopenia on this neoplasia development in RTR was, to our knowledge, never studied before, relationships between PCA and CD4 lymphopenia were studied in HIVinfected patients [25,26] . In these patients, CD4 lymphopenia was not identified as a risk factor for PCA [25] .…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, no previous study has evaluated the impact of persistent CD4 lymphocytopenia on the development of de novo genitourinary tumors (GUT) in RTR. Recent studies performed in human immunodeficiency virus (HIV) type 1 infected patients [25,26] suggested a relation between PCA occurrence and the immunosuppressive state associated with HIV infection. In these studies, HIV-infected patients had a higher rate of PCA than noninfected men of the same age.…”

mentioning

confidence: 99%

Lymphocyte Subsets in Renal Transplant Recipients with de novo Genitourinary Malignancies

Guichard¹,

Rebibou

Ducloux³

et al. 2008

Urol Int

View full text Add to dashboard Cite

Introduction: The incidence of genitourinary tumors (GUT) in renal transplant recipients (RTR) is higher than in the general population. We previously reported that CD4 lymphocytopenia is associated with a high incidence of skin cancer in RTR. Here, we investigate whether persistent CD4 T cell lymphopenia is associated with GUT occurrence. Patients and Methods: A total of 433 patients were included in this study. All patients underwent annually systematic lymphocyte subset (CD3, CD4, CD8, CD19) determination by flow cytometry. Results and Conclusion: During the follow-up period, 13 patients developed GUT: 6 patients a prostate adenocarcinoma (incidence 0.06%/year) and 7 patients a renal cell carcinoma (incidence 0.07%/year). The patients with GUT were older than those without. Both groups did not differ in posttransplant duration, dialysis mode and duration, induction regimen, or acute rejection history. No persistent CD4 lymphopenia was observed in the patients with GUT. Although CD4 T cell lymphopenia is associated with skin cancer in long-term RTR, it did not appear to be a risk factor for GUT. This suggests that other factors encountered in the setting of kidney transplantation (e.g., immunosuppressive drugs, end-stage renal failure, etc.) favor the development of GUT in RTR.

show abstract

Should HIV patients be considered a high risk group for the development of prostate cancer?

Cited by 18 publications

References 3 publications

HIV and prostate cancer: a systematic review of the literature

HIV and prostate cancer: a systematic review of the literature

Urologic complications of HIV and AIDS

Lymphocyte Subsets in Renal Transplant Recipients with de novo Genitourinary Malignancies

Contact Info

Product

Resources

About